Recommendation based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months
Back-to-back plenary presentations for LAURA and ADRIATIC Phase III trials reinforce the potential of Tagrisso and Imfinzi in early lung cancer settings
The award recognizes powerful science–industry collaborations for social good
CRESEMBA receives seven years and six months of US market exclusivity for these pediatric indications
The production started from its greenfield manufacturing facility at Aurangabad in Maharashtra
Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy
Launch innovative vitamin sublingual sprays
Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
Subscribe To Our Newsletter & Stay Updated
